News - SAb Biotherapeutics

July 30, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

July 30, 2020 08:48 AM Eastern Daylight Time SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing…

RSS

SAB Biotherapeutics Closes Series B Funding

July 17, 2020

Cows Help With COVID-19 Treatment, No Bull

June 17, 2020

Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

June 16, 2020

SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020

June 8, 2020

This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19

June 5, 2020

SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate

May 28, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

SAB Biotherapeutics Closes Series B Funding

Cows Help With COVID-19 Treatment, No Bull

Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020

This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19

SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate

Researchers Use Cows To Develop Antibody Treatment

I Am BIO | “Herd” Immunity Podcast

Convalescent Serum Lines Up As First-Choice Treatment For Coronavirus

Jodi’s Journal: The Little Biotech Company That Could Beat COVID-19

Behind SAB’s Rapid Response To COVID-19